INTRODUCTION
The immediate-early Mr 72,000 protein gene of human cytomegalovirus (hCMV) is transcribed from one of the strongest enhancer/promoters known (1, 2, 3) . The enhancer appears to be active in a broad range of host cell types (1, 4, 5) , and in comparison with various viral promoters, it has been shown to be the strongest in transient expression systems (4, 6, 7) . The hCMV IE1 enhancer/promoter has proven a versatile source of transcriptional signals for expression of heterologous proteins (5, 7, 8, 9, 10, 11) .
Expression of the hCMV major immediate-early (IE1) gene is controlled by a complex of regulatory regions, which includes upstream sequences that specifically modulate expression in cell types (12, 13) , a cluster of binding sites for nuclear factor 1 (NF1) (3, 14, 15) , and a complex enhancer (1, 3) . The transcribed region of the gene contains four exons and three introns (2, 16) . The largest of the introns, intron A, occurs within the 5' untranslated region of the gene, where the strongest of five NF1 binding sites is located (14) . While the enhancer region of this gene has been carefully studied, the possibility of regulatory signals in transcribed sequences has not been addressed until recently (17) .
To examine hCMV IE1 regulatory signals in the transcribed region, we chose to express heterologous glycoproteins, rather than synthetic reporter molecules, in a series of expression plasmids containing hCMV IE1 DNA. In defining sequences of the hCMV IE1 region that produce the highest levels of glycoprotein secretion in a transient expression system, we show that intron A contains elements that enhance expression in transformed monkey kidney cells.
MATERIALS AND METHODS

Construction of recombinant plasmids
All plasmids containing hCMV (Towne) sequences were derived from pRL103a, a 21 Kb Hind ffl (Hind ffl C) fragment of hCMV (Towne) cloned in pBR322 (18) . E. coli host strains having strong RecA phenotypes were used for all cloning steps (19) . A 5.5 Kb Hind Ul-BamHl fragment of pRL103a, containing the 5' end and upstream sequences of the major immediate-early gene, was subcloned into pBR322 for restriction mapping and sequencing. For cloning steps requiring site-directed mutagenesis, restriction endonuclease fragments were subcloned into M13 bacteriophage vectors (20) , modified by synthesis of new ( + ) strands using oligonucleotide primers (21) , and completely sequenced before replacement into the expression plasmids (22) . The complete sequence of relevant DNA from pRL103a is shown in Fig. 1 .
A backbone plasmid (pSVori) was constructed to include the SV40 origin of replication and early region polyadenylation signal, E. coli origin of replication and ampicillin resistance gene, and restriction sites for inserting hCMV IE1 fragments (Fig.2) .
pSVori is composed of a 1.5 Kb Pvu I to Pst I fragment of pSVT-2 (23) and a 0.7 Kb Sal I to Pvu I fragment of pSV7d (24) .
5' flanking and 5' untranslated sequences of the hCMV Towne IE1 region are shown schematically in Fig.3A . A 1636 bp fragment of the CMV IE1 5' sequence starting at the 3' Ssp I site, including intron A and retaining two of the five NF1 binding sites, was created as follows by site-directed mutagenesis (Fig.3B) . A Sal I site was installed 9 bp before the initiation codon. The resulting DNA was cut with Ssp I and Sal I, then ligated into the EcoRl (filled) and Sal I sites of pSVori to produce an expression vector called pCMV6 (Fig.2) . A fragment beginning at the Ssp I site and lacking intron A was prepared by site-directed mutagenesis using a 63 base synthetic oligonucleotide to precisely delete intron A and create a Sal I site 9 bp before the initiation codon (Fig.3C ). This deletion fragment was then cloned into pSVori to make pCMV5 (Fig.2) . Finally, the NF1 binding site in intron A was altered by sitedirected mutagenesis to the sequence TGGCAACTTGCCAA. This change of three bp in the spacer region produces an NF1 consensus sequence found in a middle repetitive element of the mouse genome, which has been reported not to bind NF1 (14) . After mutagenesis, the entire clone was re-sequenced to verify that no other changes had been made. The fragment (Fig.3D ) was used to make pSVori derivative pCMV6nf 1.
Expression plasmids for human t-PA were constructed using the Sal I fragment from pSV7tPA3 (25) encoding the complete human t-PA plus 99 bp of 5' untranslated DNA. This fragment was inserted into CMV IE1 plasmids pCMV5 (without intron A) and pCMV6 (with intron A). Expression plasmids for HIV-1 were of four types. The first included the entire gpl60 envelope gene with the homologous signal sequence from HIV-SF2, on a Sac I (nt 5555 ) to Xho I (nt 8460) fragment. In the second type, the envelope gene was mutagenized at the processing site for gpl20-gp41 cleavage, adding a stop codon following Arg509, to produce a secreted gpl20 with the homologous HIV signal. In the third and fourth types, the 5' end of the envelope gene was modified to place an Nhe I site upstream of Glu31 for replacement of the homologous signal of gpl20 and gpl60 with the heterologous human t-PA signal, modified to bear an Nhe I site at amino acid Ser23 to make a 25 amino acid signal sequence ending in AlaSer.
Sequence analysis DNA fragments to be sequenced were subcloned into M13 bacteriophage vectors (20) . Sequencing was carried out using the dideoxynucleotide chain termination method (22) , and compressions resolved through the use of 7-deaza-2'-deoxy-GTP (26) . The complete sequence of both DNA strands was determined by preparing single-stranded M13 templates and sequencing with a series of oligonucleotide primers synthesized on an Applied Biosystems 38OA synthesizer. Data were analyzed using Analysis Release Package software (27) .
Cell culture
Transient expression experiments were carried out using COS7 cells (monkey kidney cells transformed with SV40 T-antigen) (28) maintained in Dulbecco's modified Eagle's medium (DME) supplemented with 10% fetal bovine serum. COS7 cells were transfected with CsCl-banded plasmid DNA using a modification of a DEAE-Dextran/chloroquine diphosphate procedure (29, 30) . Monkey kidney cells carrying a temperature-sensitive SV40 Tantigen gene (ts COS) were maintained and transfected as were the COS7 cells (31) . Temperature sensitive (ts) COS cells were co-transfected with pSV2-neo (32) and selected in 400 /tg/mL G418. Negative control cell lines were transfected with pSV2-neo alone.
Assays for secreted glycoproteins Concentrations of Factor VIII (FVIII) glycoproteins secreted by transfected cells were determined using the COATEST activity assay (KabiVitrum), a sandwich ELISA for FVIII gp80 light chain (33) , and a solid phase radioimmunoassay for FVIII gp92 heavy chain (34) .
Recombinant human t-PA in the culture medium was detected using an antigen capture ELISA (Imubind™, American Diagnostics) calibrated with human t-PA (NIBSC no. 83151). Recombinant HTV-1 glycoproteins were detected using an antigen capture ELISA developed at Chiron specific for viral or recombinant HIV-SF2 envelope. The capture antibody was high titer polyclonal goat serum raised against yeast-derived recombinant gpl20 (available from the NIAID AIDS Research and Reference Reagent Program, January 1991 catalog no. 385). The detecting antibody was high titer rabbit polyclonal serum raised against the same recombinant antigen (1:100). Detection was via horse-radish peroxidase conjugated goat anti-rabbit (1:3O00, Tago code 6400). The assay was calibrated with purified recombinant gpl20 from HIV-SF2 produced in mammalian cells (35) (available from the NIAID AIDS Research and Reference Reagent Program, January 1991 catalog no. 386).
Total cytoplasmic RNA was extracted from permanent temperature sensitive (ts) COS cell lines (36) . Equivalent amounts were electrophoresed through formaldehyde agarose gels and transferred to nitrocellulose. The Sal I insert fragment from pCMV6al20SF2 was labeled with 32 P by nick translation, then hybridized to immobilized RNA under standard conditions (36) .
In vitro NF1 binding assay Nuclear extracts containing NF1 proteins were prepared from COS7 cells as described (15) . Oligonucleotides were made on an Applied Biosystems 380B DNA synthesizer. The 26 base NF1-V strand (TCTATTGGCTATATGCCAATACTCTG) and NFl-mutV strand (TCTATTGGCAACTTGCCAATACTCTG) were labeled by hybridizing a primer (CAGAGTATTGGC) and extending the duplex using the large fragment of DNA polymerase I (37). Ten fmol of each 32 P-labeled oligonucleotide were incubated separately with crude nuclear extract in 20/tL mixtures and analyzed on non-denaturing polyacrylamide gels as described (15).
RESULTS
Sequence analysis of the 5' region of hCMV (Towne) IE1 gene
The 5' region of the hCMV (Towne) major immediate-early gene was subcloned into pBR322 as a 5.5 Kb Hind IH to BamUl restriction fragment from pRL103a (18) . The sequence shown in Fig. 1 was obtained using the M13 universal primer and internal oligonucleotide primers with three overlapping M13 subclones of the following restriction endonuclease fragments: Pst I to Sac I (nt 1 -1125), Ssp I to Pvu II (nt 458-2356), and Hinc II (nt .
The sequence shown in Fig. 1 extends the known sequence of the hCMV (Towne) IE1 gene by 533 bases on the 5' side and provides the complete sequences of introns A and B. When aligned with the more extensively studied hCMV strain AD169 (1, 14, 38) , the genes are 97% homologous in non-coding and coding DNA.
The 5' end of the hCMV (Towne) IE1 gene can be divided into five regulatory regions. The first approximately 400 bp contains a tissue-specific modulator, thought to extend from nt 1 to -365 (12) . This region contains a potential stem-loop structure in the form of two 30 bp inverted repeats (nt 119-148 and 183-211) separated by 31 bp (Fig. 1) . Next there is a cluster of four binding sites for nuclear factor 1 (NF1) between nt 372 and 530 (14, 15) . The first site matches the consensus sequence TGGC/A(N) 5 GCCAA required for optimal NF1 binding, but the other three vary at one or more positions. The function of Nucleic Acids Research, Vol. 19, No. 14 3981 these clustered NF1 sites has not been established, but NF1 binding in concert with other transcription factors may activate transcription from a downstream promoter (39) .
The most important regulatory region is a complex enhancer, which spans nt -600 to -1081 (1,2,3). Many potential binding sites for well-characterized transcription factors, including Spl (CCGCCC), CRE/ATF (TGACGTCA) and NF-xB (GGGRC/A/TTYYCC) are present. Since these transcription factors are common to diverse cell types, the presence of clustered sequence motifs probably accounts for the broad spectrum and high level of activity observed for the hCMV IE1 enhancer. A strong polymerase II promoter extends from nt 1082 to the transcriptional start site at 1144 (16) Transcription is initiated within a CREB (cyclic AMP responsive element binding protein) sequence (Fig.l) .
A fifth regulatory region of the hCMV IE1 gene appears to be within transcribed sequences. Exon A (121 bp) is followed by intron A (823 bp) and exon B, in which translation is initiated (Fig.l) . Exon A contains an 18 bp element homologous to that shown to regulate the level of transcription of the CMV immediate-early promoter (17) . Searching intron A reveals no consensus motifs for Spl, CRE/ATF, NF-xB, or CREB. However, a perfect consensus site for NF1 is found at nt 1488 to 1501. Also identified in this search is a region of homology (nt 1708 to 1820) with the internal regulatory element of the quail troponin I gene (40) , which is a tissue-specific enhancer located in the first intron of a muscle-specific gene. The region of homology includes the muscle regulatory factor binding site, auxiliary binding sites I and II (41) , and a region 3' to site II. Nucleotides 1744-1751 (Fig. 1) exactly match a direct repeat spanning the muscle factor binding site and site I in the troponin I regulatory element. Overall homology is significant: p< 0.003.
Expression vectors containing hCMV transcription signals
To secrete heterologous glycoproteins from mammalian cells requires the construction of versatile expression plasmids that take advantage of high-level transient expression in COS cells (28) , and that function well when integrated into permanent cell lines. In order to assess the activity of promoter and enhancer functions supplied by hCMV IE1 sequences, the promoterless plasmid pSVori (Fig. 2) was built to contain the SV40 origin of replication, transcript cleavage and polyadenylation signals from the SV40 T-antigen gene, restriction sites suitable for inserting hCMV DNA fragments, and a prokaryotic selectable marker and origin of replication. Fig.3 illustrates the hCMV IE1 region used to construct expression vectors for this study. In preliminary experiments, all of the untranscribed regulatory regions of the hCMV EE1 gene, including the potential stem-loop structure spanning nucleotides 119 through 211, clustered NF1 sites, and enhancer/promoter sequences, were included in expression vectors. However, when the first 400 bp of the Pst I fragment were present in expression plasmids, poor expression of glycoproteins was observed in both monkey kidney cells (COS7) and in Chinese hamster ovary cells (DXB11). Deletion of these upstream modulatory sequences led Table I to high levels of expression for several mammalian glycoproteins, suggesting a negative regulatory role for this region in the two cell types. Therefore, glycoprotein expression plasmids were constructed using both transcribed and untranscribed regulatory sequences, including intron A, but lacking 5' DNA containing the potential stem-loop structure and the first two NF1 binding sites (Fig.3B) . Vectors without intron A were prepared using the fragment shown in Fig.3C . To assess the effect of the intronic NF1 binding site on expression, vectors were made using the fragment (Fig.3D ) containing a mutation in the NF1 motif in intron A.
These four fragments were inserted into pSVori (Fig.2) to make a set of complete expression plasmids into which cDNAs for human glycoproteins were placed as reporter genes. In comparative experiments described below, we examine expression of human Factor VIII (FVIII), human tissue plasminogen activator (t-PA), and human immunodeficiency virus (HIV-1) coat glycoproteins.
Comparison of the SV40 early and hCMV immediate-early promoter/enhancers
Expression levels from pSVori derivatives containing CMV IE1 promoter/enhancer sequences were compared with expression from the SV40 early promoter/enhancer using HIV-1 envelope glycoproteins as reporter molecules. A cDNA encoding HIV-1 envelope glycoprotein gpl60 was subcloned into an expression vector bearing the SV40 early promoter (pSV7d) (24) and into pCMV6, which bears the CMV IE1 enhancer/promoter with intron A (Fig.2) . These expression plasmids were transfected into COS7 cells, then supernatants and cell lysates were assayed for the expression of HIV envelope glycoprotein using a sandwich ELISA that recognizes antigens in the gpl20 portion of HIV-SF2 gpl60. Expression of gpl60 is shown in Table I. HTV-1 gpl60 expression was not detected from the SV40 early promoter if the HTV signal sequence was retained (Table I) , although expression was detected with human HIV-positive serum using indirect immunofluorescence (data not shown). In an attempt to improve expression, the homologous signal sequence was replaced with that from human t-PA, previously shown to direct high level expression of Factor VQI gp80 (24) . [Expression of HTV-1 envelope genes bearing the homologous signal sequence are rev-dependent, while genes bearing the t-PA signal are revindependent (N. Haigwood and M.-L. HammarskjOld, manuscript in preparation). All experiments shown here were done in the absence of rev from HIV-1].
Following replacement of the signal sequence with that from the human t-PA gene, expression of gpl60 was detectable from the SV40 promoter in COS7 cell lysates (Table I) . Expression was still significantly higher from the CMV IE1 enhancer/promoter, at least ten-fold higher than expression driven by the SV40 early enhancer/promoter. Earlier work (11) suggested that expression of t-PA was not significantly higher in a CMV IE1 promoter plasmid than in an SV40 late promoter vector. Results in Table I suggest that the t-PA pre-pro sequence is not sufficient to elevate SV40-driven expression to the level of CMV LEI-driven expression.
Performance of expression vectors with and without intron A
To determine the regulatory role of intron A, transient expression assays were done in the presence and absence of intron A using various glycoproteins. Expression plasmids for full-length FVIII, FVIH gp92, HIV-1 gpl20 and human t-PA were constructed either in pCMV6 (with intron A) or in pCMV5 (intron A deleted), and compared with SV40 early enhancer/promoter derivatives (Table II) . Four of five glycoproteins were secreted at higher levels when expressed with the CMV LEI enhancer/promoter than when expressed from the SV40 early enhancer/promoter: FVUI, FVIII gp92, HIV-1 gpl60, and HIV-1 gpl20 (Tables I and II) . With t-PA, the SV40E/t-PA plasmid outperformed both of the CMV IEl/t-PA derivatives. A similar result was obtained in a comparison between the SV40 late promoter and a CMV IE1 construction with t-PA (11) showing that not all glycoprotein cDNAs are best expressed under the control of the CMV IE1 enhancer/promoter. Data in Table II illustrate that expression levels of FVIII, FVIII gp92, and HIV-1 gpl20 were significantly improved when intron A was included. Thus, in cases where the CMV IE1 enhancer/promoter is more active than the SV40 enhancer/promoter, intron A contributes to this activity.
The most striking results were obtained with HIV-1 gpl20. Using the plasmid without intron A, secretion of gpl20 was approximately 2% the level seen from the expression plasmid bearing intron A (Table II) . Additional experiments, detecting gpl20 by western blotting, have yielded results consistent with these; gpl20 is expressed more than 100-fold better using the CMV enhancer/promoter plus intron A compared with the SV40 early promoter (data not shown).
Effect of mutating the NFl site in intron A
The positive effect of intron A on expression of several glycoproteins may arise by regulation of upstream enhancer/ promoter elements (42, 43, 44, 45, 46) , or by contributions to processing of stable mRNAs (47, 48, 49) . In the transient expression system used to test our plasmid constructions, mRNA stability is probably not a limiting factor. Expression from this system is more likely to be a product of plasmid replication, transcription, and post-translational processing of glycoproteins. Speculating that intron A might contain sequences that function as downstream transcriptional activators (42,43), we searched for several common transcription elements. The sequence of intron A contains only one of these elements, a consensus binding site for nuclear factor 1 (14, 15) .
Experiments shown in Table III were done to determine whether binding of NFl to the site in intron A was responsible for some or all of its positive effects. An expression plasmid was constructed using a fragment (Fig.3D ) in which the consensus NFl binding site in intron A was mutated to a sequence reported not to bind NFl (14) . Derivative plasmids for expression of FVUI gp92 and gp80 were cloned, transfected into COS7 cells, and assayed for FVIII activity. Data in Table III show that changing the NFl motif in intron A had no effect on expression of FVIII gp80 (a construction having 5' and 3' sequences derived from t-PA), but consistently reduced expression of FVIII gp92; cotransfection of the gp80 and gp92 expression plasmids confirmed the results with gp92 alone. The decrease in FVm gp 92 expression of 30-40% was not as great as the 60% observed after deletion of intron A (Table III) .
NFl binding to its consensus motif TGGC/AN 5 GCCAA has been shown to be sensitive to the sequence of flanking DNA (37) . While the NFl sequence represented in our mutant NFl site does not function as an NFl binding site in the middle repetitive element of mouse DNA (14) , NFl could bind this sequence in the context of intron A. Moreover, the composition of the five bp spacer can modulate binding affinity and expression activity over a four-fold range (39) . Data shown in Table in would be consistent with the hypothesis that the mutant NFl site in our test plasmid binds NFl, but the three mutations in the spacer reduce NFl/DNA binding affinity, leading to reduced expression.
To test this hypothesis, we performed a gel mobility retardation assay using crude nuclear extracts from COS7 cells as a source of NFl proteins. These proteins were allowed to bind labeled, double-stranded oligonucleotides representing the context and sequence of the intron A and mutant NFl sites. This assay shows differential migration of protein-bound oligonucleotides in a nondenaturing polyacrylamide gel (Fig.4) . COS7 nuclear extracts clearly contain several NF1 proteins capable of binding the mutant NF1 site in vitro (Fig.4, lanes 6 -8) . However, equivalent amounts of nuclear extract bind fewer molecules of the mutant oligomer than intron A oligomer (Fig.4, lanes 2 vs 6, etc. ). This reduction in NFl binding to the mutant sequence was observed to be between two and five fold in repeated assays (data not shown). The difference seen in NFl binding to the mutant oligonucleotide in vitro is consistent with the lower level of expression of FVII1 gp92 from the mutant expression vector. We conclude from these experiments that binding of NFl to the site in intron A can increase expression directed by the CMV IE I enhancer/promoter, but probably does not account for all of the positive effects of intron A.
Steady state mRNA transcribed from intron A-containing plasmids
To examine the quantity and size of transcripts produced from pCMV6-derived plasmids, steady state mRNA was analyzed in several HIV-l gp 120-expressing permanent cell lines. Temperature sensitive (ts) COS cells (31) were grown under permissive (33°C) conditions to induce transcription, and total cytoplasmic RNA was examined on Northern blots hybridized with a HTV-1 gpl20-specific probe. Shown for one such cell line (Fig. 5) , the predominant species is larger than predicted for a spliced transcript polyadenylated at the SV40 early site (upper arrow, -2.6 kb). A minor species appears at the size expected for correctly spliced and polyadenylated mRNA (lower arrow, 1.6 kb). The same sizes and proportions of mRNA were observed in these cell lines at the non-permissive (40°C) temperature, but at lower levels (data not shown).
The larger (predominant) cytoplasmic species probably results from read-through of the weak SV40 polyadenylation signal supplied by the vector, with cleavage and polyadenylation occurring at a cryptic site approximately one Kb downstream in the prokaryotic /3-lactamase gene (50, 51) . Cytoplasmic RNA transcribed from construct pSVF8-302 (see Table II ), which has the same polyadenylation signal and downstream prokaryotic sequences, hybridizes with pBR322 DNA (data not shown).
It has been suggested that one effect of introns in mammalian expression vectors may be to improve the efficiency of RNA processing and transport to the cytoplasm (49) . The large amount of cytoplasmic message found in cells transfected with intron Acontaining plasmids is consistent with this function.
DISCUSSION
While untranscribed regions of highly-expressed genes have been extensively studied, the role of transcribed sequences has only recently been appreciated. Our study suggests that intron A of the hCMV IE1 gene activates its promoter in transformed monkey kidney cells. In earlier work, including introns in expression plasmids was found to increase levels of expression in both transient systems and permanent cell lines (47, 49, 52) . Transcriptional activation (42, 43, 44, 45, 46) and mRNA stabilization (47, 48) have been suggested as possible mechanisms underlying this effect.
Recent work indicates that regulatory elements in transcribed sequences may be integral regulators of promoters (17, 42, 43, 53) . Strong enhancer-like elements have been found in transcribed sequences of many genes, e.g., the enhancer found in the intron between the J H and /t constant region exons of immunoglobulin heavy chain genes (53, 54) . More regulatory elements occur in the first introns of structural genes such as the mouse ribosomal protein gene rpL32 (45) , the mouse alpha 1 type I collagen gene (46) , and the chicken troponin I gene (40, 41) . These elements appear to be promoter-specific.
In the present case, intron A of the hCM V IE 1 gene seems to contain only one consensus site for a well-characterized transcription factor, an NFl binding site. Our data show that NFl binding to this site has a small effect on the activity of the hCM V IE1 enhancer/promoter. A search of intron A for enhancer-like elements reveals homology with the internal regulatory element of the troponin I gene. However, since our assays were performed in non-muscle cells, this enhancer-like element could be functioning by binding related transcription factors present in transformed kidney cells. When a pCMV6 (intronA-containing) Factor VIII plasmid was introduced into transgenic mice, FVIII glycoprotein was expressed primarily in muscle tissues (T.Mikkelsen, B.Chapman, N.Din, J.Ingerslev, P.Kristensen, K.Poulsen, and J.P.Hjorth, in preparation). This tissue specificity was not seen in transgenic mice when intron A was absent from the CMV IE1 sequences (10). These results indicate that sequences in intron A, which are homologous to muscle-specific regulatory elements, may be functioning in a tissue-specific manner in vivo.
Not all cDNAs behave the same way in these vectors. We conclude that no host/vector combination is likely to be universal for good glycoprotein expression, and emphasize that the results presented above do not provide data on relative levels of transcription or mRNA stability. Instead, we have assessed the role of the CMV IE1 regulatory region in a complex, multi-step process. Expression of glycoproteins, unlike artificial reporter molecules, may be limited less by transcription and more by protein folding, glycosylation, and other post-translational processes. Positive effects of intron A have been demonstrated in a transient, high copy number system, and recently in permanent hamster cell lines. The CMV IE1 enhancer/promoter with intron A has produced very high levels of glycoproteins in a system where mRNA stability contributes to robust expression (Chapman and Haigwood, unpublished). Our results indicate that heterologous expression vectors can be optimized by inclusion of intron A with other elements of the hCMV IE1 enhancer/promoter.
